The prognostic value of nestin expression in newly diagnosed glioblastoma: Report from the Radiation Therapy Oncology Group

Prakash Chinnaiyan, Meihua Wang, Amyn M. Rojiani, Philip J. Tofilon, Arnab Chakravarti, K. Kian Ang, Hua Zhong Zhang, Elizabeth Hammond, Walter Curran, Minesh P. Mehta

Research output: Contribution to journalArticle

37 Scopus citations

Abstract

Background: Nestin is an intermediate filament protein that has been implicated in early stages of neuronal lineage commitment. Based on the heterogeneous expression of nestin in GBM and its potential to serve as a marker for a dedifferentiated, and perhaps more aggressive phenotype, the Radiation Therapy Oncology Group (RTOG) sought to determine the prognostic value of nestin expression in newly diagnosed GBM patients treated on prior prospective RTOG clinical trials. Methods: Tissue microarrays were prepared from 156 patients enrolled in these trials. These specimens were stained using a mouse monoclonal antibody specific for nestin and expression was measured by computerized quantitative image analysis using the Ariol SL-50 system. The parameters measured included both staining intensity and the relative area of expression within a specimen. This resulted into 3 categories: low, intermediate, and high nestin expression, which was then correlated with clinical outcome. Results: A total of 153 of the 156 samples were evaluable for this study. There were no statistically significant differences between pretreatment patient characteristics and nestin expression. There was no statistically significant difference in either overall survival or progression-free survival (PFS) demonstrated, although a trend in decreased PFS was observed with high nestin expression (p = 0.06). Conclusion: Although the correlation of nestin expression and histologic grade in glioma is of considerable interest, the presented data does not support its prognostic value in newly diagnosed GBM. Further studies evaluating nestin expression may be more informative when studied in lower grade glioma, in the context of markers more specific to tumor stem cells, and using more recent specimens from patients treated with temozolomide in conjunction with radiation.

Original languageEnglish (US)
Article number32
JournalRadiation Oncology
Volume3
Issue number1
DOIs
StatePublished - Sep 25 2008
Externally publishedYes

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging

Fingerprint Dive into the research topics of 'The prognostic value of nestin expression in newly diagnosed glioblastoma: Report from the Radiation Therapy Oncology Group'. Together they form a unique fingerprint.

  • Cite this

    Chinnaiyan, P., Wang, M., Rojiani, A. M., Tofilon, P. J., Chakravarti, A., Ang, K. K., Zhang, H. Z., Hammond, E., Curran, W., & Mehta, M. P. (2008). The prognostic value of nestin expression in newly diagnosed glioblastoma: Report from the Radiation Therapy Oncology Group. Radiation Oncology, 3(1), [32]. https://doi.org/10.1186/1748-717X-3-32